Relay Therapeutics, Inc.
NASDAQ:RLAYBiotechnology
+$0.41 today
- Market cap
- $3.52B
- Beta
- 1.75
- P/E (TTM)
- -10.5
- EPS (TTM)
- -$1.52
Volume 1.88M
Average 3.70M
Returns on capital
Relay Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-48.8%
avg -16.8%
ROIC
-50.5%
avg -31.0%
ROA
-44.5%
avg -27.6%
Analysis
ROA is currently the strongest return metric at -44.5% versus its period average of -27.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Sanjiv K. Patel MBBS | Chief Executive Officer, President & Director | USD 1.13M | 52 | — | — |
Donald A. Bergstrom | President of Research & Development | USD 817.66K | 54 | 396.88K | 0.23% |
Thomas Catinazzo | Chief Financial Officer | USD 694.11K | 50 | 103.67K | 0.06% |
Peter Rahmer | Chief Corporate Development Officer | USD 670.67K | 44 | 222.90K | 0.13% |
Mark Murcko | Founder & Independent Director | USD 65.92K | 66 | 32.95K | 0.02% |
Soo-Yeun Lim | Senior Vice President & General Counsel | — | — | — | — |
David Elliot Shaw | Founder | — | 75 | — | — |
Matthew Jacobson | Founder | — | — | — | — |
Dorothee Kern | Founder | — | — | — | — |
Jim Watters | Chief Scientific Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 28, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
37
$127.18M
Net Transaction Value
−$127.18M
Net selling
Most Active
Catinazzo Thomas
16 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 28, 26Oct 28, 2026 | Bergstrom Donald A Direct | Sell | $41.9K$41,932.24 |
| Oct 28, 26Oct 28, 2026 | Catinazzo Thomas Direct | Sell | $27.4K$27,352.78 |
| Oct 28, 26Oct 28, 2026 | Rahmer Peter Direct | Sell | $14K$14,020.86 |
| Oct 7, 26Oct 7, 2026 | Patel Sanjiv Direct | Sell | $872.4K$872,401.90 |
| Oct 6, 26Oct 6, 2026 | Catinazzo Thomas Direct | Sell | $325.4K$325,354.38 |
| Oct 6, 26Oct 6, 2026 | Catinazzo Thomas Direct | Sell | $4K$3,967.56 |
| Sep 8, 26Sep 8, 2026 | Bergstrom Donald A Direct | Sell | $161.8K$161,814.10 |
| Sep 8, 26Sep 8, 2026 | Catinazzo Thomas Direct | Sell | $335.6K$335,559.98 |
| Sep 8, 26Sep 8, 2026 | Patel Sanjiv Direct | Sell | $912.9K$912,889.06 |
| Aug 26, 26Aug 26, 2026 | Rahmer Peter Direct | Sell | $90.3K$90,295.24 |
1–10 of 37
Summary
Insiders reported 0 buys worth $0.00 and 37 sells worth $127.18M over the last 12 months. That adds up to net selling of $127.18M. Catinazzo Thomas was the most active insider with 16 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | +123.2% | +97.7% (5yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Recent growth has been strongest in Revenue at +123.2% over three years. Forward estimates point to Revenue at +97.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Relay Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about RLAY's management, answered from reported figures.
Who manages RLAY?
Relay Therapeutics, Inc. (RLAY) lists 10 active executives. The top listed executive is Soo-Yeun Lim, Senior Vice President & General Counsel.
Are RLAY insiders buying or selling?
Recent insider activity shows net selling of $87.37M.
Continue the stock analysis
Jump to another research area for this company.